Biodesix Statistics

Total Valuation

Biodesix has a market cap or net worth of $40.42 million. The enterprise value is $86.68 million.

Market Cap	40.42M
Enterprise Value	86.68M

Important Dates

The next estimated earnings date is Wednesday, August 6, 2025, after market close.

Earnings Date	Aug 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Biodesix has 146.56 million shares outstanding. The number of shares has increased by 63.31% in one year.

Current Share Class	146.56M
Shares Outstanding	146.56M
Shares Change (YoY)	+63.31%
Shares Change (QoQ)	-0.04%
Owned by Insiders (%)	50.77%
Owned by Institutions (%)	30.98%
Float	61.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.53
Forward PS	0.45
PB Ratio	3.65
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.16
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.22, with a Debt / Equity ratio of 5.77.

Current Ratio	2.22
Quick Ratio	1.90
Debt / Equity	5.77
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.37

Financial Efficiency

Return on equity (ROE) is -1,454.41% and return on invested capital (ROIC) is -30.82%.

Return on Equity (ROE)	-1,454.41%
Return on Assets (ROA)	-23.33%
Return on Invested Capital (ROIC)	-30.82%
Return on Capital Employed (ROCE)	-44.39%
Revenue Per Employee	$272,758
Profits Per Employee	-$148,051
Employee Count	273
Asset Turnover	0.86
Inventory Turnover	12.88

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -82.43% in the last 52 weeks. The beta is 0.96, so Biodesix's price volatility has been similar to the market average.

Beta (5Y)	0.96
52-Week Price Change	-82.43%
50-Day Moving Average	0.34
200-Day Moving Average	0.98
Relative Strength Index (RSI)	43.66
Average Volume (20 Days)	1,716,861

Short Selling Information

The latest short interest is 5.26 million, so 3.59% of the outstanding shares have been sold short.

Short Interest	5.26M
Short Previous Month	5.63M
Short % of Shares Out	3.59%
Short % of Float	8.49%
Short Ratio (days to cover)	0.23

Income Statement

In the last 12 months, Biodesix had revenue of $74.46 million and -$40.42 million in losses. Loss per share was -$0.28.

Revenue	74.46M
Gross Profit	58.36M
Operating Income	-32.37M
Pretax Income	n/a
Net Income	-40.42M
EBITDA	-26.58M
EBIT	-32.37M
Loss Per Share	-$0.28

Full Income Statement

Balance Sheet

The company has $17.60 million in cash and $63.87 million in debt, giving a net cash position of -$46.26 million or -$0.32 per share.

Cash & Cash Equivalents	17.60M
Total Debt	63.87M
Net Cash	-46.26M
Net Cash Per Share	-$0.32
Equity (Book Value)	11.06M
Book Value Per Share	0.08
Working Capital	16.31M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$41.94 million and capital expenditures -$3.07 million, giving a free cash flow of -$45.01 million.

Operating Cash Flow	-41.94M
Capital Expenditures	-3.07M
Free Cash Flow	-45.01M
FCF Per Share	-$0.31

Full Cash Flow Statement

Margins

Gross margin is 78.38%, with operating and profit margins of -43.47% and -54.28%.

Gross Margin	78.38%
Operating Margin	-43.47%
Pretax Margin	-54.28%
Profit Margin	-54.28%
EBITDA Margin	-35.69%
EBIT Margin	-43.47%
FCF Margin	n/a

Dividends & Yields

Biodesix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-63.31%
Shareholder Yield	-63.31%
Earnings Yield	-99.99%
FCF Yield	-111.35%

Analyst Forecast

The average price target for Biodesix is $1.75, which is 534.52% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$1.75
Price Target Difference	534.52%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biodesix has an Altman Z-Score of -6.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.27
Piotroski F-Score	3